APA (7th ed.) Citation

Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., . . . Nakagawa, K. (2019). [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. International journal of cancer, 145(12), 3414-3424. https://doi.org/10.1002/ijc.32408

Chicago Style (17th ed.) Citation

Takegawa, Naoki, et al. "[fam‐] Trastuzumab Deruxtecan, Antitumor Activity Is Dependent on HER2 Expression Level Rather than on HER2 Amplification." International Journal of Cancer 145, no. 12 (2019): 3414-3424. https://doi.org/10.1002/ijc.32408.

MLA (9th ed.) Citation

Takegawa, Naoki, et al. "[fam‐] Trastuzumab Deruxtecan, Antitumor Activity Is Dependent on HER2 Expression Level Rather than on HER2 Amplification." International Journal of Cancer, vol. 145, no. 12, 2019, pp. 3414-3424, https://doi.org/10.1002/ijc.32408.